IMV Inc.
IMV
Rang in Aktien
#35074
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Aktienkurs
$0.82959892
Zuletzt synchronisiert: 2023-05-23
Marktkapitalisierung
$4.16M
Veränderung (1 Tag)
-0.04%
Veränderung (1 Jahr)
82,959,792.06%
Land
CA
Handel IMV Inc. (IMV)
Kategorie
Healthcare
Kursverlauf für IMV Inc. (IMV)
Höchster Schlusskurs: $0.00 am 2024-04-01
Niedrigster Schlusskurs: $2.79 am 2009-10-01
Niedrigster Schlusskurs: $2.79 am 2009-10-01
Kursverlauf der Aktie von IMV Inc. von 2009 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2024 | -99.62% |
| 2023 | -99.90% |
| 2022 | -80.41% |
| 2021 | -58.37% |
| 2020 | 14.77% |
| 2019 | -48.18% |
| 2018 | 1.97% |
| 2017 | 209.96% |
| 2016 | -4.32% |
| 2015 | -11.63% |
| 2014 | 46.23% |
| 2013 | 3.39% |
| 2012 | 10.27% |
| 2011 | -50.45% |
| 2010 | -42.36% |
| 2009 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
